Aim immunotech engages business development firm, azenova, llc to catalyze partnering, development and commercialization efforts for ampligen® pipeline programs

Ocala, fla., oct. 17, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim”) today announced it has entered into an agreement with azenova, llc (“azenova”), a professional business development (bd) consulting firm, to support efforts to partner aim's pipeline programs with a particular focus on the company's lead asset, ampligen®, for the treatment of various malignant solid tumors.
AIM Ratings Summary
AIM Quant Ranking